A Study of Sacituzumab Govitecan in People With Mesothelioma
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
Mesothelioma|Mesotheliomas Pleural|Mesothelioma; Pleura
DRUG: Sacituzumab govitecan-hziy
Overall Response Rate, Clinical efficacy of Sacituzumab Govitecan/SG determined by overall response rate by modified (m)RECIST criteria v1.1. Overall response rate defined as participants who achieve complete response or partial response as best overall response by modified RECIST v1.1 criteria for mesothelioma, 2 years
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.